$613.51 Million in Sales Expected for Maximus, Inc. (NYSE:MMS) This Quarter
Analysts expect Maximus, Inc. (NYSE:MMS) to announce $613.51 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Maximus’ earnings, with the highest sales estimate coming in at $619.20 million and the lowest estimate coming in at $607.34 million. Maximus posted sales of $617.09 million during the same quarter last year, which suggests a negative year over year growth rate of 0.6%. The business is expected to issue its next quarterly earnings report before the market opens on Thursday, August 3rd.
On average, analysts expect that Maximus will report full-year sales of $613.51 million for the current financial year, with estimates ranging from $2.45 billion to $2.46 billion. For the next year, analysts anticipate that the business will report sales of $2.57 billion per share, with estimates ranging from $2.52 billion to $2.62 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Maximus.
Maximus (NYSE:MMS) last issued its quarterly earnings results on Thursday, May 4th. The health services provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $622 million for the quarter, compared to the consensus estimate of $620.24 million. Maximus had a return on equity of 26.21% and a net margin of 8.18%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 earnings per share.
A number of research analysts have commented on MMS shares. Jefferies Group LLC lowered shares of Maximus from a “buy” rating to a “hold” rating and lifted their price objective for the company from $63.00 to $64.00 in a research note on Friday, May 5th. Maxim Group lowered shares of Maximus from a “buy” rating to a “hold” rating and set a $66.00 price objective on the stock. in a research note on Thursday, May 4th. They noted that the move was a valuation call. ValuEngine lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. KeyCorp restated a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. Finally, Canaccord Genuity restated a “buy” rating and issued a $62.00 price objective on shares of Maximus in a research note on Friday, April 7th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $61.00.
In other news, Director Paul R. Lederer sold 8,210 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $61.83, for a total transaction of $507,624.30. Following the transaction, the director now directly owns 51,984 shares in the company, valued at $3,214,170.72. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Russell A. Beliveau sold 1,500 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $63.82, for a total transaction of $95,730.00. Following the transaction, the director now owns 41,829 shares in the company, valued at $2,669,526.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,846 shares of company stock worth $6,893,986. Company insiders own 3.10% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP purchased a new position in shares of Maximus during the fourth quarter worth about $258,000. Norges Bank bought a new position in shares of Maximus during the fourth quarter valued at $25,597,000. WCM Investment Management CA raised its position in shares of Maximus by 7.5% in the first quarter. WCM Investment Management CA now owns 24,411 shares of the health services provider’s stock valued at $1,518,000 after buying an additional 1,700 shares during the last quarter. Bank of Montreal Can raised its position in shares of Maximus by 56.5% in the first quarter. Bank of Montreal Can now owns 125,084 shares of the health services provider’s stock valued at $7,780,000 after buying an additional 45,167 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of Maximus by 3.0% in the first quarter. Capstone Asset Management Co. now owns 6,972 shares of the health services provider’s stock valued at $434,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 98.03% of the company’s stock.
Shares of Maximus (NYSE MMS) traded down 0.26% during trading on Friday, hitting $60.39. The stock had a trading volume of 149,183 shares. Maximus has a one year low of $43.69 and a one year high of $64.97. The stock’s 50 day moving average price is $62.48 and its 200-day moving average price is $60.48. The stock has a market cap of $3.91 billion, a P/E ratio of 19.80 and a beta of 1.40.
The company also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.045 per share. The ex-dividend date is Friday, August 11th. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.30%. Maximus’s dividend payout ratio (DPR) is 5.86%.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.